Searching…
Apr 10, 2023 · Pembrolizumab combined with chemotherapy improves survival and progression-free survival in patients with squamous non-small cell lung cancer.
承認時評価資料：国際共同第Ⅲ相試験（KEYNOTE-407試験） Paz-Ares L et al. N Engl J Med 2018; 379: 2040-2051 Paz-Ares L et al. N Engl J Med 2018; 379: 2040-2051 Supplementary Data（Protocol） Paz-Ares L et al. N Engl J Med 2018; 379: 2040-2051...
Pembrolizumab (pembro) + platinum-based chemotherapy (chemo) significantly prolonged OS and PFS compared with placebo + chemo in patients (pts) with previously untreated, metastatic squamous NSCLC in the phase III KEY...
Oct 23, 2023 · 在一项III 期、随机、开放式研究中，将该方案与组织学特异性化疗单独进行了比较，该研究包括非鳞状和鳞状NSCLC患者。
KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patien...
肺癌 KEYNOTE-407プラチナ併用化学療法もしくは抗PD-1抗体であるペムブロリズマブ（Pemb）単剤療法 (PD-L1発現スコア（TPS）≧50％の場合) が扁平上皮非小細胞肺癌 (NSCLC) の標準初回治療となっている。非扁平上皮NSCLCの一次治療では、Pembとプラチナ併用化学療法の併用が全生存期間を延長させること ...
Sep 25, 2018 · Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1 ...
